Keywords
biomarker
inflammation
cytokines
Abstract
Methods currently used in brain vascular disorder diagnostics are neither fast enough nor clear-out; thus, there exists a necessity of finding new types of testing which could enlarge and complete the actual panel of diagnostics or be an alternative to current methods. The discovery of sensitive and specific biomarkers of ischemic brain stroke will improve the effects of treatment and will help to assess the progress or complications of the disease. The relevant diagnosis of ischemic stroke (IS) within the first 4.5 hours after the initial symptoms allows for the initiation of treatment with recombinant tissue plasminogen activators which limits the magnitude of negative changes in the brain and which enhance the final effectiveness of therapy. The potential biomarkers which are under investigation are substances involved in the processes of coagulation and fibrinolysis, and are of molecules released from damaged vascular endothelial cells and from nerves and cardiac tissue. The analyzed substances are typical of oxidative stress, apoptosis, excitotoxicity and damage of the blood brain barrier.
References
1. Brouns R., De Deyn P.P.: The complexity of neurobiological processes in acute ischemic stroke. Clin. Neurol. Neurosurg., 111, 483, 2009.
2. Castellanos M. et al.: Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study. Stroke, 38, 1855, 2007.
3. Chen S. et al.: Asymmetric Dimethyarginine as Marker and Mediator in Ischemic stroke. Int. J. Mol. Scien., 13, 15983, 2012.
4. Chorong H., Ki-Sook H.: Apolipoprotein B/A1 Ratio as Risk Factor for Cerebral Ischemic Stroke. Ewha Med. J., 35, 21, 2012.
5. Craig J.S. et al.: Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurology, 4, 2, 2004.
6. Fouda A.Y. et al.: Anti-inflammatory IL-10 is upregulated in both hemispheres after experimental ischemic stroke: Hypertension blunts the response. Exp. Transl Stroke Med., 5, 12, 2013.
7. Greisenegger S. et al.: Biomarkers and Mortality After Transient Ischemic Attack and Minor Ischemic Stroke Population-Based Study, Stroke, 46, 659,2015.
8. Hanson E. et al.: Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke. J. Thromb. Haemost., 9, 275, 2011.
9. Heeb M.J. et al.: Low protein Z levels and risk of ischemic stroke: differences by diabetic status and gender. Blood Cells, Mol. Dis., 29, 139, 2002.
10. Iskra T. et al.: Hemostatyczne markery uszkodzenia śródbłonka w udarze niedokrwiennym spowodowanym chorobami małych i dużych naczyń. Pol. Merkur. Lekarski, 21, 429, 2006.
11. Jauch E.C. et al.: Association of Serial Biochemical Markers With Acute Ischemic Stroke. Stroke, 37, 2508, 2006.
12. Jensen J.K. et al.: Osteoprotegerin concentrations and prognosis in acute ischaemic stroke. J. Intern. Med., 267, 410, 2010.
13. Jickling G.C., Frank R. Sharp F.R.: Biomarker Panels in Ischemic Stroke. Stroke, 46, 915, 2015.
14. Jong-Ho P. et al.: High Levels of Apolipoprotein B/AI Ratio Are Associated With Intracranial Atherosclerotic Stenosis. Stroke, 42, 3040, 2011.
15. Jóźwicka M., Głąbiński A.: The search for inflammatory biomarkers of ischaemic stroke. Aktualn. Neurol., 11, 106, 2011.
16. Kim M.H. et al.: Plasma biomarkers in the diagnosis of acut ischemic stroke. Ann. Clin. Lab. Sci., 40, 336, 2010.
17. Kim S.J., Moon G.J., Banga O.Y.: Biomarkers for Stroke. Journal of Stroke, 15(1), 27, 2013.
18. Lioutas V.A., Novak V.: Intranasal insulin neuroprotection in ischemic stroke. Neural. Regen. Res., 11, 400, 2016.
19. 19. Marquardt L. et al.: Course of platelet activation markers after ischemic stroke. Stroke, 33, 2570, 2002.
20. Nishiyama Y. et al.: Asymmetric dimethylaarginine (ADMA) as a possible risk marker for ischemic stroke. J. Neurol. Scien., 290, 12, 2010.
21. Palasik W.: Homocysteina – czynnik ryzyka występowania niedokrwiennego udaru mózgu. Postępy Nauk Medycznych, 14, 18, 2001.
22. Park S.Y. et al.: Plasma heart-type fatty acid binding protein level in acute ischemic stroke: comparative analysis with plasma S100B level for diagnosis of stroke and prediction of long-term clinical outcome.Cli. Neurol. Neurosurg., 115, 405, 2013.
23. Radwan W., Rabbah A., Saber H., Elghonemi M.: A new marker for ischemic cerebrovascular stroke: Phosphorylated Neurofilament H. The Egyptian Journal of Critical Care Medicine, 1, 105, 2013.
24. Rodriguez-Grande B.: Pentraxin 3 mediates neurogenesis and angiogenesis after cerebral ischaemia, Journal of Neuroinflammation, 12, 15, 2015.
25. Rothstein L., Jickling G.C.: Ischemic stroke biomarkers in blood.Biomarkers in Medicine, 7, 37, 2013.
26. Ryu W.S. et al.: Pentraxin 3: a novel and independent prognostic marker in ischemic stroke. Atherosclerosis, 220, 581, 2012.
27. Shenhar-Tsarfaty S. et al.: Interleukin-6 as an early predictor for one-year survival following an ischaemic stroke/transient ischaemic attack. Int. J. Stroke, 5, 16, 2010.
28. Shimizu H. et al.: Plasma homocysteine concentrations and the risk of subtypes of cerebral infarction. Cerebrovasc Dis., 13, 9, 2002.
29. Smolders B., Lemmens R., Thijs V.: Lipoprotein (a) and stroke: a meta-analysis of observational studies. Strok,. 38, 1959, 2007.
30. Song T.J. et al.: Association of plasma osteopro¬tegerin levels with stroke severity and functional outcome in acute ischaemic stroke patients. Biomarkers, 17, 738, 2012.
31. Tanne D. et al.: Soluble intercellular adhesionmolecule-1 and risk of future ischemic stroke: a nestedcase-control study from the Bezafibrate Infarction Prevention(BIP) study cohort. Stroke, 33, 2182, 2002.
32. Tomita H. et al.: Elevated plasma brain natriuretic peptide levels independent of heart disease in acut ischemic stroke: correlation with stroke severity. Hypertens. Res., 31, 1695, 2008.
33. Tran H.A., Eikelboom J.W.: Role of protein Z in stroke. Options Cardio. Med., 9, 191, 2007.
34. Tuttolomondo A. et al.: Plasma levels of inflammatory and thrombotic/fibrinolytic markers in acute ischemic strokes: relationship with TOAST subtype, outcome and infarct site. J. Neuroimmunol., 215, 84, 2009.
35. Waje-Andreassen U. et al.: IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol. Scand., 111, 360, 2005.
36. Węglewski A.: Biochemiczne markery uszkodzenia mózgu. Postępy Psychiatrii i Neurologii, 12, 111, 2003.
37. Welsh P. et al.: Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc Dis., 27, 247, 2009.
38. Wiseman S. et al.: Blood Markers of Coagulation, Fibrinolysis, Endothelial Dysfunction and Inflammation in Lacunar Stroke versus Non-Lacunar Stroke and Non-Stroke: Systematic Review and Meta-Analysis. Cerebrovasc Dis., 37, 64, 2014.
39. Wunderlich M.T. et al.: Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke. J. Neurol., 252, 718, 2005.
40. Yi-Chinn W., Wen-Hai Ch.: Neutrophil Gelatinase-Associated Lipocalin and Matrix Metalloproteinase-9 as Potential Biomarkers for Stroke: A Pilot Study. J. Neurol. Neurophysiol., 6, 2, 2015.
41. Yip H.K. et al.: Link between platelet activity and outcomes after an ischaemic stroke. Cerebrovasc. Dis., 20, 120-128, 2005.
42. Żerdziński M., Rychlik M., Partyka R.: Rola selektyn w rozwoju odpowiedzi zapalnej. Journal of Laboratory Diagnostics, 48, 347, 2012.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2017 Authors